We found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitlePaclitaxel, not bevacizumab, was primarily responsible for the favorable effects seen in the RIBBON-2 trial.AuthorsKesikli, Altug; Kilickap, SaadettinPublicationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 4, p461ISSN1527-7755Publication typeCommentaryDOI10.1200/JCO.2011.40.2305